Accelerated Corneal CXL for Progressive Keratoconus: 1-Year Follow-up

Bozkurt, Ercument

Accelerated Corneal CXL for Progressive Keratoconus: 1-Year Follow-up

Friday, April 17, 2015

KIOSKS (San Diego Convention Center)

Ercument Bozkurt, MD

Engin B. Ozgurhan, MD

Betul I. Sezgin Akçay, MD

Tugba Kurt

Yusuf Yildirim, MD

Necip Kara, MD

Ahmet Demirok, MD

Purpose
To evaluate the 1 year clinical results of accelerated collagen crosslinking (CXL) in patients with progressive keratoconus.

Methods
In this retrospective interventional cases series, 42 eyes of 42 patients with progressive keratoconus were enrolled. All patients underwent accelerated CXL with settings of 18 mW/cm2 for 5 minutes (total surface dose of 5.4 J/cm2). Mean outcome measures were K_flat , K_steep, K_apex, K _average and thinnest corneal thickness (TCT) . The efficacy and safety of procedure were assessed during 1 year follow-up.

Results
Mean±SD age of 22 female and 20 male was 26.64±3.81 years . K_flat value decreased from baseline by 46.65±1.61 D to 45.99±3.53 D at last visit, and the K_steep value decreased from 49.93±3.11D to 49.66±3.83 (p<0,05 for both). K _average value decreased from 48.29±2.91 D to 47.82±2.81 and the K_apex value decreased from baseline by 57.88±6.15 to 56.43±5.45 D at last visit, (p<0,05 for both). The TCT was 436.98±39.25µm preoperatively while it was 437.55±41.55 at 12 month postoperatively (p=0,701).

Conclusion
Accelerated CXL (18-mW/cm2) halted the keratoconus progression without relevant side effects in patients with progressive keratoconus during 12 months follow up.